Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …
The Herald | HeraldOnline.com SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product … Rigel Pharma (RIGL) Starts Clinical Studies For Asthma, Discoid Lupus Rigel Begins Trial With Advanced Proprietary Therapeutic Product Candidates |
View full post on asthma – Google News